# Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

> **NCT00854620** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 9 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Kidney Disease
- Kidney Cancer

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00854620
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-07
- **Final completion:** 2011-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854620, "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00854620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*